| The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway | Annual Review of Biochemistry | 2010 | 1.9K |
| Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination | Cell | 2002 | 832 |
| Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen | Journal of Clinical Oncology | 2010 | 615 |
| Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study | Circulation | 2007 | 596 |
| Proliferation marker Ki-67 in early breast cancer | Journal of Clinical Oncology | 2005 | 593 |
| A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas | Journal of Clinical Pathology | 1995 | 581 |
| Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy | Journal of Clinical Oncology | 2013 | 462 |
| Mechanisms of tamoxifen resistance | Endocrine-Related Cancer | 2004 | 448 |
| Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis | Circulation | 2003 | 390 |
| Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase | Journal of Clinical Oncology | 2005 | 368 |
| Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial | Journal of Clinical Oncology | 2008 | 360 |
| Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer | Cancer Research | 2016 | 344 |
| Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer | British Journal of Cancer | 2004 | 315 |
| Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women | Journal of the National Cancer Institute | 2006 | 296 |
| Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study | Journal of Clinical Oncology | 2002 | 273 |
| Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population | Lancet Oncology, The | 2013 | 266 |
| ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer | Cancer Discovery | 2011 | 242 |
| A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer | Clinical Cancer Research | 2010 | 240 |
| Substrate specificity of gamma-secretase and other intramembrane proteases | Cellular and Molecular Life Sciences | 2008 | 229 |
| Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists | Journal of Clinical Oncology | 2005 | 228 |
| Aromatase inhibitors for breast cancer: lessons from the laboratory | Nature Reviews Cancer | 2003 | 220 |
| Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer | Cancer Research | 1995 | 209 |
| Proinflammatory profile within the grossly normal aged human aortic wall | Hypertension | 2007 | 204 |
| The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer | Breast Cancer Research and Treatment | 2009 | 195 |
| Mass spectrometry and glycomics | OMICS A Journal of Integrative Biology | 2010 | 190 |
